Dabigatran Etexilate - CAS 211915-06-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
Publictions citing BOC Sciences Products
  • >> More
Prazaxa; BIBR 1048; BIBR-1048
1.Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Harenberg J1. Thromb Res. 2016 Apr;140 Suppl 1:S165-7. doi: 10.1016/S0049-3848(16)30117-7.
A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain anticoagulation in the therapeutic range of vitamin K antagonists. The therapeutic range of anti-factor Xa activity during therapy with low-molecular weight heparins and danaparoid are less well and of direct oral anticoagulants (DOAC) poorly defined. The relation of aPTT and INR values to thrombotic and bleeding events are well established despite a large variation of values in affected patients. The relation of coagulation values of the other anticoagulants to clinical events is open. The value of determination in cancer patients is higher because of the increased risk for thrombotic and bleeding events of this patient group. Several activities are currently undertaken to certify methods for in vitro diagnostic testing for DAOCs.
2.Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models.
Lo-Ciganic WH1, Gellad WF, Huskamp HA, Choudhry NK, Chang CH, Zhang R, Jones BL, Guclu H, Richards-Shubik S, Donohue JM. Med Care. 2016 Apr 25. [Epub ahead of print]
BACKGROUND: Variation in physician adoption of new medications is poorly understood. Traditional approaches (eg, measuring time to first prescription) may mask substantial heterogeneity in technology adoption.
3.Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance.
Inoue H1, Uchiyama S2, Atarashi H3, Okumura K4, Koretsune Y5, Yasaka M6, Yamashita T7, Ohnishi M8, Yagi N9, Fukaya T10; J-Dabigatran Surveillance Investigators. J Arrhythm. 2016 Apr;32(2):145-50. doi: 10.1016/j.joa.2015.11.008. Epub 2016 Jan 16.
BACKGROUND/AIM: A post-marketing surveillance (PMS) study is being conducted to investigate the safety and effectiveness of the long-term use of dabigatran etexilate (dabigatran) in Japanese patients with nonvalvular atrial fibrillation (NVAF). Results of an interim analysis of this prospective cohort study including patient characteristics and adverse drug reactions (ADRs) collected up to September 17, 2014 are reported here.
4.Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Spronk HM1, De Jong AM2, Verheule S3, De Boer HC4, Maass AH2, Lau DH3, Rienstra M2, van Hunnik A3, Kuiper M3, Lumeij S3, Zeemering S3, Linz D5, Kamphuisen PW6, Ten Cate H1, Crijns HJ7, Van Gelder IC2, van Zonneveld AJ4, Schotten U8. Eur Heart J. 2016 Apr 12. pii: ehw119. [Epub ahead of print]
AIMS: Atrial fibrillation (AF) produces a hypercoagulable state. Stimulation of protease-activated receptors by coagulation factors provokes pro-fibrotic, pro-hypertrophic, and pro-inflammatory responses in a variety of tissues. We studied the effects of thrombin on atrial fibroblasts and tested the hypothesis that hypercoagulability contributes to the development of a substrate for AF.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Thrombin Products

CAS 211915-06-9 Dabigatran Etexilate

Dabigatran Etexilate
(CAS: 211915-06-9)

Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki va...

CAS 429658-95-7 Dabigatran ethyl ester

Dabigatran ethyl ester
(CAS: 429658-95-7)

Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran provides a stable anticoagulation effect w...

CAS 211914-51-1 Dabigatran

(CAS: 211914-51-1)

Dabigatran is a very potent anticoagulant, shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of...

GYKI-14451 sulfate
(CAS: 83861-29-4)

GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.

(CAS: 60503-05-1)

H-D-Phe-Pro-arginal is a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. It has a similar efficacy ...

CAS 141396-28-3 Argatroban

(CAS: 141396-28-3)

Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with ...

CAS 83997-16-4 GYKI 14166

GYKI 14166
(CAS: 83997-16-4)

Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was ...

CAS 871576-03-3 Flovagatran

(CAS: 871576-03-3)

Flovagatran is a thrombin inhibitor originated by Trigen Holdings AG. In Dec 2010, Phase-II for Thrombosis was discontinued.

CAS 30827-99-7 AEBSF HCl

(CAS: 30827-99-7)

AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

CAS 192939-46-1 Ximelagatran

(CAS: 192939-46-1)

Ximelagatran, an ester prodrug of melagatran, with anticoagulant effect, is the first member of direct thrombin inhibitors that can be taken orally.

CAS 137215-12-4 odiparcil

(CAS: 137215-12-4)

Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for th...

CAS 872728-81-9 Dabigatran etexilate mesylate

Dabigatran etexilate mesylate
(CAS: 872728-81-9)

Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. It is a reversible and selective, direct thrombin inhibitor (DTI).

CAS 74863-84-6 Argatroban

(CAS: 74863-84-6)

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.

(CAS: 69201-89-4)

GYKI14451 is a synthetic tripeptide inhibitor of thrombin. It has anti-atherosclerotic activity.


VE-1902 is a novel and selective inhibitor of thrombin. Study in vivo and in vitro showed that VE-1902 inhibits thrombin via binding to it reversibly.

Bivalirudin Trifluoroacetate

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding ...

CAS 496775-62-3 Eltrombopag Olamine

Eltrombopag Olamine
(CAS: 496775-62-3)

Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thr...

CAS 137339-65-2 Sfllrnpndkyepf

(CAS: 137339-65-2)

SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide and causes platelet aggregation (EC50 = 4 μM) and secretion .

Chemical Structure

CAS 211915-06-9 Dabigatran Etexilate

Quick Inquiry

Verification code

Featured Items